Health Catalyst (HCAT) Tops Q4 EPS by 6c, Offers Guidance

Health Catalyst (NASDAQ: HCAT) reported Q4 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $69.2 million versus the consensus estimate of $68.26 million.

GUIDANCE:

Health Catalyst sees Q1 2023 revenue of $70.3-72.3 million, versus the consensus of $71.6 million.

Health Catalyst sees FY2023 revenue of $290-295 million, versus the consensus of $298.7 million.

For earnings history and earnings-related data on Health Catalyst (HCAT) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• Viking Holdings Ltd (VIK) Tops Q2 EPS by 36c